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Abstract
Background: The association between polymorphisms on 15q25.1 and lung cancer has been widely evaluated; however,
the studies have yielded contradictory results. We sought to investigate this inconsistency by performing a comprehensive
meta-analysis on two polymorphisms (CHRNA3 gene: rs1051730 and AGPHD1 gene: rs8034191) on 15q25.1.
Methods: Data were extracted from 15 and 14 studies on polymorphisms rs1051730 and rs8034191 involving 12301/14000
and 14075/12873 lung cancer cases/controls, respectively. The random-effects model was applied, addressing
heterogeneity and publication bias.
Results: The two polymorphisms followed Hardy-Weinberg equilibrium for all studies (P.0.05). For rs1051730-G/A, carriers
of A allele had a 36% increased risk for lung cancer (95% confidence interval [CI]: 1.27–1.46; P,0.0005), without
heterogeneity (P = 0.258) or publication bias (PEgger = 0.462). For rs8034191-T/C, the allelic contrast indicated that C allele
conferred a 23% increased risk for lung cancer (95% CI: 1.08–1.4; P = 0.002), with significant heterogeneity (P,0.0005),
without publication bias (PEgger = 0.682). Subgroup analyses suggested that the between-study heterogeneity was derived
from ethnicity, study design, matched information, and lung cancer subtypes. For example, the association of
polymorphisms rs1051730 and rs8034191 with lung cancer was heterogeneous between Caucasians (OR = 1.32 and 1.22;
95% CI: 1.25–1.44 and 1.05–1.42; P,0.0005 and 0.008, respectively) and East Asians (OR = 1.51 and 1.03; 95% CI: 0.76–3 and
0.47–2.27; P = 0.237 and 0.934, respectively) under the allelic model, and this association was relatively strengthened under
the dominant model. There was no observable publication bias for both polymorphisms.
Conclusions: Our findings demonstrated that CHRNA3 gene rs1051730-A allele and AGPHD1 gene rs8034191-T allele might
be risk-conferring factors for the development of lung cancer in Caucasians, but not in East-Asians.
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for lung cancer, the driving genes and genetic variants that
determine the development of lung cancer are unclear.
The chromosome 15q25.1 region has been identified as a
hotspot for lung cancer susceptibility by recent genome-wide
association (GWA) studies [5,6,7,8]. Results of genetic association
studies for nicotine dependence, smoking behavior, and smokingrelated diseases have converged to implicate the chromosome
15q25.1 region. The relationship between polymorphisms
rs1051730 in CHRNA3 gene and rs8034191 in the AGPHD1 gene
and lung cancer risk or related phenotypes has been widely
investigated. As stated by McClellan and King, many if not most
of the genetic polymorphisms that are reported to be associated
with common disorders in GWA studies are factually spurious

Introduction
Lung cancer is the most common malignancy and the firstleading cause of cancer mortality, with an estimated 1.3 million
new cases diagnosed annually in the world [1,2]. The well-known
risk factors for lung cancer include cigarette smoking and exposure
to ionizing radiation (e.g., radon, medical imaging). Accumulating
evidence has suggested that genetic factors may contribute to the
variation in susceptibility to lung cancer. It is widely accepted that
lung cancer is a complex multifactorial disease, attributed to the
interaction of genetic factors with environmental factors [3,4].
Despite intensive efforts devoted to investigating the genetic factors
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associations caused by subtle differences in ancestry between the
populations being studied (known as ‘‘cryptic population stratification’’) [9]. Moreover, based on the fact that individual studies
with insufficient sample sizes lack sufficient statistical power to
detect the common variants with tiny effects on lung carcinogenesis, the results are not reproducible. To derive a more precise
estimation and investigate the inconsistency, we evaluated the
effect of two polymorphisms rs1051730 and rs8034191 on the risk
of lung cancer, addressing heterogeneity and publication bias.

Statistical Analysis
Data management and statistical analyses were conducted using
STATA software (StataCorp, Texas, USA, version 11.0 for
Windows). Deviation from Hardy-Weinberg equilibrium was
tested by x2 or Fisher’s exact test in control groups. Irrespective
of between-study heterogeneity, a random-effects model using the
DerSimonian and Laird method was implemented to bring the
individual effect-size estimates together, and the estimate of
heterogeneity was taken from the Mantel-Haenszel model [12].
Unadjusted OR and 95% CI were used to compare allelic and
dominant contrast between cases and controls.
Between-study heterogeneity was assessed by the inconsistency
index I2 statistic (ranging from 0 to 100%), which was documented
for the percentage of the observed between-study variability due to
heterogeneity rather than by chance, with higher values suggesting
the existence of heterogeneity [13,14]. In the case of betweenstudy heterogeneity, we examined the study characteristics that
could stratify the studies into subgroups with homogeneous effects.
To estimate the extent to which one or more covariates explained
the heterogeneity, we employed meta-regression, as an extension
of random-effects meta-analysis.
Cumulative meta-analysis was conducted to identify the
influence of the first published study on the subsequent publications, and the evolution of the combined estimates over time
according to the ascending date of publication. To identify
potentially influential studies, we performed influential analysis
(also known as sensitivity analysis) by removing an individual study
each time to check whether any of these estimates biased the
overall estimate.
The funnel plot and Egger’s test were applied to assess
publication bias [15]. Egger’s test can detect funnel plot
asymmetry by determining whether the intercept deviates
significantly from zero in a regression of the standardized effect
estimates against their precision. Trim and fill method was also
used to estimate the number and outcomes of potentially missing
studies resulting from publication bias. A probability ,0.05 was
considered significant except for the I2 and Egger’s statistic, for
which a significance level was defined as ,0.1.

Methods
We performed this analysis in accordance with the guidelines of
the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) statement [10] (see flowchart S1 and checklist
S1).

Search Strategy for Identification of Studies
We searched the PubMed and EMBASE databases for articles
published before January 2012, using the Boolean combinations of
subject terms (CHRNA3 OR AGPHD1 OR LOC123688) AND
(lung cancer OR carcinoma OR neoplasm) AND (gene OR
polymorphism OR allele OR genotype OR variant OR mutation).
Articles were restricted to English-language and human studies.
The full text of the retrieved articles was scrutinized to decide
whether information on the topic of interest was included.
Reference lists of these retrieved articles and systematic reviews
were also checked for citations of articles not initially identified.
For articles involving more than one geographic or ethnic
heterogeneous group, each group was treated separately. When
genotype frequency was not reported, we contacted the authors to
obtain the relevant information.

Inclusion/Exclusion Criteria
Articles were included in this meta-analysis if they 1) examined
the hypothesis that CHRNA3 gene rs1051730 polymorphism and/
or AGPHD1 gene rs8034191 polymorphism were associated with
lung cancer risk; 2) followed a nested case-control or case-control
or cross-sectional study design; and 3) provided sufficient
information on genotype/allele counts between cases and controls
to estimate the odds ratio (OR) and the corresponding 95%
confidence interval (95% CI). The relatively complete and recent
results were extracted when there were multiple articles involving
the same population.

Results
Search of Studies
Based on our search strategy, the primary screening produced
40 potentially relevant articles, of which 12 met the inclusion
criteria in an attempt to evaluate the association of CHRNA3 gene
rs1051730 and/or AGPHD1 gene rs8034191 polymorphisms with
lung cancer risk [5,16,17,18,19,20,21,22,23,24,25,26]. A flow
diagram schematized the process of selecting and excluding
articles with specific reasons (Figure 1). The 12 qualified articles
were published between 2008 and 2011 involving 16 studies with 9
in Caucasians, 4 in East Asians, 2 in African-Americans, and 1 in
mixed (Caucasian, African-American and Hispanic) populations.
The quality score of studies ranged from 7 to 10 (mean: 8.5) out of
a maximal score of 12. In detail, there were 11 (15) and 10 (14)
articles (studies) for rs1051730 and rs8034191 polymorphisms
involving 12301/14000 and 14075/12873 lung cancer cases/
controls, respectively.

Extracted Information
The following information was extracted independently and
entered into separate databases by two authors (MG and WN)
from each qualified study: first author’s last name, publication
date, population ethnicity, study design, baseline characteristics of
the study population including age, ethnicity, sex, smoking status,
and the genotype counts in cases and controls. Any encountered
discrepancy was adjudicated by a discussion until a consensus was
reached.

Quality Score Assessment
The study quality was assessed by using a quality assessment
score developed for genetic association studies by Thakkinstian
et al [11]. Total scores ranged from 0 (worst) to 12 (best). The
criteria for quality assessment of the genetic association between
two studied polymorphisms and lung cancer are described in
Table S1.
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Study Characteristics
The baseline characteristics of all qualified studies are summarized in Table 1. Genotype distributions of two polymorphisms
were in Hardy-Weinberg equilibrium for all studies (P.0.05). Ten
of 16 qualified studies were matched on age or sex or smoking
status between cases and controls [16,18,19,21,22,24,25,26]. Five
2
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Figure 1. Flow diagram of search strategy and study selection.
doi:10.1371/journal.pone.0037970.g001

significant 23% increased risk for lung cancer (95% CI: 1.08–1.4;
P = 0.002) with heterogeneity (I2 = 87.2%; P,0.0005). The risk
magnitude was slightly weakened under the dominant model
(OR = 1.2; 95% CI: 1.02–1.42; P = 0.03; I2 = 85.2%; P,0.0005)
(Table 3).
For both polymorphisms, as reflected by the visual funnel plot
inspection (Figure 2-A and 2-C) and Egger’s regression asymmetry
statistic, there was low probability of publication bias (P = 0.742
and 0.682 for rs1051730 and rs8034191, respectively). Further
evidence of selective publication suggested that there were no
missing studies required to make the funnel plot symmetrical for
both polymorphisms (Figure 3-B and 3-D).

studies were hospital-based [16,19,23,26], and the rest were
population-based. Three studies involved non-small-cell lung
cancer as an end point, and one study involved squamous cell
lung carcinoma as an end point. The frequencies of CHRNA3 gene
rs1051730-A allele ranged widely between Caucasians and East
Asians with African-Americans in between. For example in control
groups, the rs1051730-A allele ranged from 29.45% to 37.14% in
Caucasians, from 1.39% to 3.3% in East Asians, and from 16.15%
to 19.85% in African-Americans. The observation was similar for
AGPHD1 gene rs8034191-C allele, with frequencies ranging from
23.04% to 39.47% in Caucasian controls, from 1.82% to 3.72% in
East Asian controls, and from 16.15% to 31.44 in AfricanAmerican controls.

Cumulative and Influential Analyses
Overall Analysis

In the cumulative meta-analysis, across all genetic models we
found no evidence suggesting that the first published study that
reported a potentially significant result then triggered subsequent
publication replication. The influential analysis showed that no
single study influenced the overall results significantly for both
polymorphisms (data not shown).

Due to the sparseness of the mutant alleles of both studied
polymorphisms in East Asians and to maximize the statistical
power to detect an association, we considered the risk effect of two
polymorphisms under both allelic and dominant models.
The overall comparison of CHRNA3 gene rs1051730-A allele
yielded a remarkably increased risk for lung cancer (OR = 1.33;
95% CI: 1.24–1.44; P,0.0005) relative to the rs1051730-G allele;
however, there was moderate evidence of between-study heterogeneity (I2 = 57.8%; P = 0.003). The risk magnitude was slightly
potentiated under the dominant model (OR = 1.36; 95% CI:
1.27–1.46; P,0.0005), but heterogeneity was absent (I2 = 18.4%;
P = 0.258) (Table 2). Likewise for AGPHD1 gene rs8034191-T/C
polymorphism, as compared with T allele, the C allele conferred a
PLoS ONE | www.plosone.org

Subgroup Analysis
In view of significant heterogeneity and to seek for its potential
sources, we performed a panel of subgroup analyses on ethnicity,
matched information, study design, and disease type.
Grouping studies by descent of populations indicated that the
odds of developing lung cancer was significantly augmented in
African-Americans for both polymorphisms, and was non-signif3
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Table 1. The baseline characteristics of all qualified studies in this meta-analysis.

First author

Disease type Match

Ethnicity

Design

Age, years

Gender (Males, %)

Cases

Controls

Cases

Controls

Zienolddiny S et al.

NSCLC

age, sex, smoking

Caucasian

population

60

60

76.99

76.14

Schwartz AG et al.

NSCLC

age, sex, race

Caucasian

population

NA

NA

NA

NA

Schwartz AG et al.

NSCLC

age, sex, race

African-American

population

NA

NA

NA

NA

Liu P et al.

lung cancer

NA

Caucasian

population

61.3

75.6

42.27

58.9

Liu P et al.

lung cancer

NA

Caucasian

population

64.6

57.1

56.1

54.9

Liu P et al.

lung cancer

NA

Caucasian

population

64.5

60.7

49.9

35.3

Spitz MR et al.

lung cancer

age, sex, race

Mixed*

population

NA

NA

NA

NA

Amos CI et al.

lung cancer

NA

Caucasian

hospital

62.1

61.1

57

56.6

Girard N et al.

lung cancer

age

Caucasian

population

NA

NA

NA

NA

Girard N et al.

lung cancer

age

Japanese

population

NA

NA

NA

NA

Broderick P et al.

lung cancer

NA

Caucasian

population

NA

NA

NA

NA

Shiraishi K et al.

lung cancer

NA

Japanese

hospital

60

50

73

60

Kohno T et al.

LSCC

sex, smoking

Japanese

hospital

62.7

62.5

90

57

Sakoda LC et al.

lung cancer

age, sex, smoking

Caucasian

population

NA

NA

67.3

66.6

Amos CI et al.

lung cancer

age, sex, race

African-American

hospital

62.4

55.7

54.82

41.24

Wu C et al.

lung cancer

age, sex

Chinese

hospital

NA

NA

69.3

31.1

Author

Smoking status (%)
Cases

Quality score rs1051730-A (%)
Controls

rs8034191-C (%)

Cases

Controls

Cases

Controls

Zienolddiny S et al. current/former: 79.7/20.3

80.9/19.1

9

42.61

36.12

41.48

36.44

Schwartz AG et al.

current/former: 17.6/82.4

52.9/47.1

9

41.19

37.02

41.19

37.02

Schwartz AG et al.

current/former: 10.2/89.8

45.1/54.9

9

19.31

16.15

19.31

16.15

Liu P et al.

current/never: 86.6/13.4

6.4/93.6

7

40.72

29.45

43.56

29.22

Liu P et al.

current/former/never: 43.9/56.1/0

55.2/44.8/0

7

39.71

33.41

39.65

33.47

Liu P et al.

current/former/never: 27.9/65.8/6.25

23.0/40.1/36.9

7

39.29

31.6

39.99

31.71

Spitz MR et al.

NA

NA

8

39.62

33.47

NA

NA

Amos CI et al.

current/former/never: 47.8/52.3/0

42.2/57.8/0

10

39.77

33.47

39.81

33.69

Girard N et al.

NA

NA

8

34.57

37.14

35.64

39.47

Girard N et al.

NA

NA

8

1.63

1.42

1.63

2.63

Broderick P et al.

NA

NA

8

NA

NA

18.78

23.04

Shiraishi K et al.

current/never: 79/21

39/61

9

3.32

1.39

3.52

1.82

Kohno T et al.

current/never: 97/3

45/55

8

3.34

1.54

NA

NA

Sakoda LC et al.

current/former: 72.4/27.6

72.4/27.6

10

40.74

34.24

40.68

34.2

Amos CI et al.

current/former/never: 48.82/40.04/11.13

37.37/36.08/26.55 9

33.4

19.85

41.97

31.44

Wu C et al.

current/former/never: 52.5/8.7/38.8

27.7/8.8/63.5

2.74

3.3

2.81

3.72

10

Abbreviations: NSCLC, non-small-cell lung cancer; SLCC, lung squamous cell carcinoma; NA, not available.
*Mixed ethnicity included Caucasian, African-American and Hispanic.
doi:10.1371/journal.pone.0037970.t001

under both allelic and dominant models (Tables 2 and 3), and the
quality of heterogeneity was not improved.
In subgroup analysis by study design, association of both studied
polymorphisms with lung cancer was potentiated in hospital-based
studies under allelic model (rs1051730: OR = 1.56, 95% CI: 1.1–
2.21, P = 0.012; and rs8034191: OR = 1.31, 95% CI: 0.96–1.79,
P = 0.092), whereas under dominant model, this association was
potentiated in population-based studies (rs1051730: OR = 1.39,
95% CI: 1.31–1.48, P,0.0005; and rs8034191: OR = 1.25, 95%
CI: 1.03–1.51, P = 0.021). Restricting analysis to the non-small-cell
lung cancer observed no evidence of heterogeneity, and found that
the risk magnitude was significant but relatively weakened under

icant or remarkably lowered in East Asians for CHRNA3 gene
rs1051730 polymorphism (allelic model: OR = 1.51; 95% CI:
0.76–3.0; P = 0.237; and dominant model: OR = 1.22; 95% CI:
0.59–2,52; P = 0.592) (Table 2), and AGPHD1 gene rs8034191
polymorphism (allelic model: OR = 1.03; 95% CI: 0.47–2.27;
P = 0.934; and dominant model: OR = 0.72; 95% CI: 0.52–0.99;
P = 0.043) (Table 3). In contrast, there were no material changes in
risk estimates in Caucasians for both polymorphisms. Upon
stratification by the matched information on age or gender or
smoking status between cases and controls, the risk estimates were
relatively weakened in matched studies for both polymorphisms

PLoS ONE | www.plosone.org
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Table 2. Overall and subgroup analyses of CHRNA3 gene rs1051730 polymorphism with the odds of developing lung cancer under
allelic and dominant models.

Overall & subgroups

Total studies

Studies (cases/
controls), n(n/n)

15 (12301/14000)

Allelic model: A vs. G

Dominant model: AA+AG vs. GG
2

OR; 95% CI; P

I (%); Px2; PEgger

OR; 95% CI; P

I2 (%); Px2; PEgger

1.33; 1.24–1.44; ,0.0005

57.8; 0.003; 0.742

1.36; 1.27–1.46; ,0.0005

18.4; 0.258; 0.462

Ethnicity
Caucasian

8 (6955/9001)

1.32; 1.25–1.4; ,0.0005

24.0; 0.238; 0.342

1.39; 1.31–1.49; ,0.0005

0.0; 0.831; 0.357

East Asian

4 (2898/2657)

1.51; 0.76–3.0; 0.237

82.1; 0.001; 0.623

1.22; 0.59–2.52; 0.592

66.9; 0.049; 0.517

African-American

2 (594/615)

1.57; 0.97–2.54; 0.064

81.8; 0.019; NA

1.38; 1.02–1.87; 0.034

NA

Mixed

1 (1854/1727)

1.3; 1.18–1.44; ,0.0005

NA

1.35; 1.18–1.55; ,0.0005

NA

Matched
Yes*

10 (5826/6877)

1.27; 1.13–1.42; ,0.0005

57.1; 0.013; 0.891

1.31; 1.15–1.48; ,0.0005

38.3; 0.113; 0.637

NA

5 (6475/7123)

1.41; 1.27–1.55; ,0.0005

58.1; 0.049; 0.675

1.4; 1.3–1.51; ,0.0005

0.0; 0.853; 0.827

Study design
Hospital

5 (4162/3741)

1.56; 1.1–2.21; 0.012

82.7; ,0.0005; 0.493

1.24; 0.79–1.96; 0.348

78.9; 0.009; 0.971

Population

10 (8139/10259)

1.32; 1.26–1.39; ,0.0005

6.4; 0.383; 0.312

1.39; 1.31–1.48; ,0.0005

0.0; 0.931; 0.34

Type of lung cancer
Mixed

11 (10676/12021)

1.35; 1.24–1.48; ,0.0005

65.5; 0.001; 0.838

1.34; 1.23–1.46; ,0.0005

34.6; 0.141; 0.133

NSCLC

3 (1251/1655)

1.24; 1.1–1.38; ,0.0005

0.0; 0.76; 0.619

1.38; 1.18–1.61; ,0.0005

0.0; 0.683; 0.372

LSCC

1 (374/324)

2.21; 1.05–4.63; 0.036

NA

2.25; 1.06–4.76; 0.034

NA

Abbreviations: NA, not available; OR, odds ratio; 95% CI, 95% confidence interval; NSCLC, non-small-cell lung cancer; LSCC, lung squamous cell carcinoma.
*Matched on age or sex or smoking.
doi:10.1371/journal.pone.0037970.t002

allelic model (rs1051730: OR = 1.24, 95% CI: 1.1–1.38,
P,0.0005; and rs8034191: OR = 1.21, 95% CI: 1.08–1.36,
P = 0.001), whereas this magnitude was significantly strengthened
under dominant model (rs1051730: OR = 1.38, 95% CI: 1.18–

1.61, P,0.0005; and rs8034191: OR = 1.35, 95% CI: 1.16–1.58,
P,0.0005).

Table 3. Overall and subgroup analyses of AGPHD1 gene rs8034191 polymorphism with the odds of developing lung cancer
under allelic and dominant models.

Overall & subgroups

Studies (cases/
controls), n(n/n)

Dominant model: CC+CT vs. TT

Allelic model: C vs. T
OR; 95% CI; P

I2 (%); Px2; PEgger

OR; 95% CI; P

I2 (%); Px2; PEgger

14 (14075/12837)

1.23; 1.08–1.4; 0.002

87.2; ,0.0005; 0.682

1.2; 1.02–1.42; 0.03

85.2; ,0.0005; 0.536

Caucasian

9 (10968/9897)

1.22; 1.05–1.42; 0.008

90.3; ,0.0005; 0.68

1.26; 1.06–1.51; 0.011

87.1; ,0.0005; 0.921

East Asian

3 (2513/2325)

1.03; 0.47–2.27; 0.934

86.2; 0.001; NA

0.72; 0.52–0.99; 0.043

0.0; 0.762; NA

African-American

2 (594/615)

1.39; 1.1–1.76; 0.006

32.6; 0.223; NA

1.38; 1.02–1.87; 0.034

NA

Total studies

Ethnicity

Matched
Yes*

8 (3588/4807)

1.17; 1.02–1.35; 0.029

60.1; 0.014; 0.139

1.17; 0.96–1.43; 0.127

62.6; 0.014; 0.123

NA

6 (10487/8030)

1.34; 1.07–1.67; ,0.0005

94.0; ,0.0005; 0.217

1.27; 0.96–1.66; 0.09

93.1; ,0.0005; 0.988

Study design
Hospital

4 (3777/3409)

1.31; 0.96–1.79; 0.092

82.1; 0.001; 0.974

0.99; 0.56–1.76; 0.982

89.3; 0.002; NA

Population

10 (10289/9428)

1.2; 1.03–1.41; 0.024

89.3; ,0.0005; 0.588

1.25; 1.03–1.51; 0.021

85.9; ,0.0005; 0.79

Mixed

11 (12824/11183)

1.23; 1.04–1.45; 0.014

90.1; ,0.0005; 0.73

1.15; 0.93–1.42; 0.211

89.0; ,0.0005; 0.459

NSCLC

3 (1251/1654)

1.21; 1.08–1.36; 0.001

0.0; 0.944; 0.27

1.35; 1.16–1.58; ,0.0005 0.0; 0.859; 0.207

Lung cancer type

Abbreviations: NA, not available; OR, odds ratio; 95% CI, 95% confidence interval; NSCLC, non-small-cell lung cancer.
*Matched on age or sex or smoking.
doi:10.1371/journal.pone.0037970.t003
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Figure 2. Funnel and filled funnel plots for studies investigating the effect of CHRNA3 gene polymorphism rs1051730 (A and B) and
AGPHD1 gene polymorphism rs8034191 (C and D) on the risk of lung cancer.
doi:10.1371/journal.pone.0037970.g002

smokers). Among these variables, the association of CHRNA3 gene
rs1051730 (correlation coefficient: 0.48, P = 0.069) and AGPHD1
gene rs8034191 (correlation coefficient: 0.57, P = 0.043) polymor-

Meta-regression analysis
To identify other sources of heterogeneity, we undertook metaregression analysis of age (mean or median value), sex (male
percent), and smoking rate (percentage of current and former

Figure 3. Meta-regression of smoking percent in lung cancer patients on in-allele risk estimates of CHRNA3 gene rs1051730 (A) and
AGPHD1 gene rs8034191 (B) polymorphisms for occurrence of lung cancer. For each study, OR is shown by the middle of the blue solid
circle whose upper and lower extremes represent the corresponding 95% CI. OR values were calculated for the current smokers against nonsmokers
(including former smokers) when available or ex-smokers against never-smokers otherwise. The green dotted line is plotted by fitting OR and
smoking percent in cases for the included studies.
doi:10.1371/journal.pone.0037970.g003

PLoS ONE | www.plosone.org

6

June 2012 | Volume 7 | Issue 6 | e37970

Lung Cancer and 15q25.1: A Meta-Analysis

confounders were extracted from recent publications (after the
year 2008) from professional cancer journals as reflected by the
high quality score. Additionally, smoking is by far the major
contributor to lung cancer, accounting for about 90% of the lung
cancer incidence [32]. Previous studies demonstrated that
polymorphisms in the CHRNA3 gene were associated with an
increased risk of smoking initiation, indicating a potential
genotype-phenotype interaction [33].
The strengths of this study include the relatively large sample size,
no deviation from Hardy-Weinberg equilibrium, and the high
quality of the qualified studies. However, our current study should
be interpreted with several technical limitations in mind. Firstly,
most of the studies in this meta-analysis were case-control studies,
which are susceptible to selection bias by including only nonfatal
cases. Secondly, because only published studies in English were
retrieved and the ‘‘grey’’ literature (articles in languages other than
English) was not included, publication bias might be possible, even
though our funnel plots and statistical tests did not show it.
However, asymmetry in the funnel plot, being either visually
interpreted or statistically tested, may result from an essential
difference between the small and larger studies that arises from
inherent between-study heterogeneity [34]. Because currently we
have no golden standard to compare the results of funnel plot tests
[34], Egger’s test and the usual funnel plot have been challenged.
We cannot completely rule out a low probability that small negative
studies are missing from the plot. Nevertheless, the trim and fill
method suggested no missing studies required to make the funnel
plot symmetrical for both polymorphisms. Thirdly, the single locus–
based nature of meta-analysis precluded the possibility of gene-gene
and gene-environment interactions, as well as haplotype-based
effects, suggesting that additional studies assessing these aspects are
necessary. Fourthly, we focused only on two polymorphisms on
15q25.1 and did not consider other candidate genes or polymorphisms. It is likely that the studied polymorphisms by itself make a
minor contribution to risk prediction in lung cancer patients, but
whether the two polymorphisms when integrated with other risk
factors will enhance the prediction requires further investigation.
Taken together, we have expanded previously individual studies
by providing the convincing evidence that CHRNA3 gene
rs1051730-A allele and AGPHD1 gene rs8034191-T allele might
be risk-conferring factors for the development of lung cancer in
Caucasians, but not in East-Asians. We have strengthened the
previous findings on the association of high smoking rate with
increased lung cancer risk. Further studies should investigate the
markers on and adjacent to 15q25.1 to clarify whether the present
association is causal or due to linkage disequilibrium.

phisms with lung cancer risk was observed in cases with a high
smoking rate under the allelic model (Figure 3).

Discussion
Via a comprehensive meta-analysis, we evaluated the association
of two common polymorphisms on 15q25.1 with the risk of lung
cancer. Overall results demonstrated that CHRNA3 gene rs1051730A allele and AGPHD1 gene rs8034191-T allele might be riskconferring factors for the development of lung cancer in Caucasians,
but not in East-Asians. Although potential sources of heterogeneity
could not be easily eliminated, the present study, to our knowledge, is
the first meta-analysis to date dealing with the association of these
two polymorphisms with lung cancer susceptibility.
We identified ethnicity as a potential source of between-study
heterogeneity by subgroup analysis. Genetic heterogeneity is
inevitable in disease identification strategy [27]. We found that
the association of rs1051730 and rs8034191 polymorphisms with
lung cancer risk was heterogeneous between Caucasians and East
Asians. The significance was observed only in the former, which
consisted with the results of GWA studies from western
populations. We also have noticed remarkable differences in
CHRNA3 gene rs1051730-A allele and AGPHD1 gene rs8034191C allele between Caucasians and East Asians, making it very
difficult to detect the weak association in Asians unless examining
a very large population. This suggests that different genetic
backgrounds may cause this discrepancy or that different
populations may have different linkage disequilibrium patterns.
The studied polymorphisms may be in linkage with another causal
variant in one ethnic population but not in another [28]. For
example, the rs1051730 polymorphism is in complete linkage
disequilibrium with the potentially pathogenic allele of rs16969968
(D398N) in the CHRNA5 gene [17,29]. We therefore speculate
that polymorphism rs1051730 may have a pleiotropic effect on the
etiology of lung carcinogenesis across different ethnic groups. In
view of the divergent genetic backgrounds, it is necessary to
construct a database of polymorphisms related to lung cancer in
each ethnic/racial group.
Besides the disturbing influence of ethnicity on overall estimate,
any estimate should be treated with caution when studies were
stratified by study design. In this meta-analysis, for both
polymorphisms, the risk estimates in hospital-based studies were
stronger than that in population-based studies. Besides the
relatively small sample size, drawbacks of hospital-based studies
should not be disregarded, as population stratification remains an
important issue [30]. Two studies had recruited subjects from only
one hospital, and thus there might be a narrow socioeconomic
profile for both cases and controls. In addition, poor comparability
between cases and controls in hospital-based studies might exert a
confounding effect on the true association in light of a regional
specialty for the disease and the differential hospitalization rates
between cases and controls [31]. In contrast, subjects drawn from
the community or the general population might be more
representative of the population, making the results from
population-based studies more convincing. Considering the wider
confidence intervals of estimates, more studies are required to
quantify the effect size reliably.
Furthermore, our meta-regression analysis found an association
of two studied polymorphisms with lung cancer risk in patients
with a higher smoking rate. We defined smoking rate based on the
percentage of current and former smokers if available. This
definition is unlikely to undermine our observation since the
exclusion of ever-smoking might lead to an underestimation of the
risk for lung cancer. Moreover, our data on smoking and other
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